Q-Line Biotech Ltd (QLINE) — shareholding pattern, promoter holding, financials and share price
About Q-Line Biotech Ltd (QLINE)
Q-Line Biotech Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as QLINE and on the BSE under scrip code 95940. Its ISIN is INE1G2W01011.
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents. [1]
Listed peers in Medical Equipment & Supplies: Tarsons Products Ltd, Laxmi Dental Ltd, OSEL Devices Ltd, Fabtech Technologies Ltd, Vasa Denticity Ltd, Hemant Surgical Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹549.05 a share on 10 Jul 2026, Q-Line Biotech Ltd (QLINE) was valued at a price-to-earnings ratio of 22.98x against an industry P/E of 44.11x and a price-to-book of 2.62x on a book value of ₹209.24 per share. Solomo computes return on equity of 22.63% and return on capital employed of 19.42% from filed results.
- P/E
- 22.98x
- Industry P/E
- 44.11x
- P/B
- 2.62x
- EPS (TTM)
- ₹28.63
- Book value / share
- ₹209.24
- ROE
- 22.63%
- ROCE
- 19.42%
- ROA
- 9.98%
- Debt / equity
- 0.92x
- Dividend yield
- 0%
- EBITDA margin
- 30.07%
- 52-week range
- ₹431 – ₹600
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Q-Line Biotech Ltd (QLINE) reported revenue of ₹342 crore, net profit of ₹56 crore and earnings per share of ₹34.24. That compares with revenue of ₹314 crore and net profit of ₹28 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹198 crore and net profit ₹34 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 183 | 203 | 314 | 342 |
| Net profit (₹ cr) | 32 | 34 | 28 | 56 |
| EPS (₹) | 203.81 | 218.67 | 178.6 | 34.24 |
| Measure | 1Y |
|---|---|
| Sales growth | 54.08% |
| Profit growth | 13.26% |